Salvage treatment of multi-refractory primary immune thrombocytopenia with CD19 CAR T cells
Top Cited Papers
- 4 January 2025
- journal article
- letter
- Published by Elsevier in The Lancet
- Vol. 405 (10472) , 25-28
Abstract
No abstract availableKeywords
Funding Information
- European Regional Development Fund
This publication has 9 references indexed in Scilit:
- Anti–CD19 CAR T Cells in Refractory Immune Thrombocytopenia of SLENew England Journal of Medicine, 2024
- B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseasesThe Lancet Neurology, 2024
- CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-upNew England Journal of Medicine, 2024
- Anti-CD19 CAR T cells for refractory myasthenia gravisThe Lancet Neurology, 2023
- CAR T-cell therapy in autoimmune diseasesThe Lancet, 2023
- Abnormalities of bone marrow B cells and plasma cells in primary immune thrombocytopeniaBlood Advances, 2021
- Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatmentBlood, 2020
- Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphomaNature Medicine, 2020
- Clinical updates in adult immune thrombocytopeniaBlood, 2017